Prospective determination of the hormonal response after cessation of luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer
- 1 May 1999
- Vol. 53 (5), 898-902
- https://doi.org/10.1016/s0090-4295(99)00061-8
Abstract
No abstract availableThis publication has 13 references indexed in Scilit:
- TIME TO NORMALIZATION OF SERUM TESTOSTERONE AFTER 3-MONTH LUTEINIZING HORMONE-RELEASING HORMONE AGONIST ADMINISTERED IN THE NEOADJUVANT SETTING: IMPLICATIONS FOR DOSING SCHEDULE AND NEOADJUVANT STUDY CONSIDERATIONJournal of Urology, 1998
- Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancerInternational Journal of Radiation Oncology*Biology*Physics, 1998
- Improved Survival in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy and GoserelinNew England Journal of Medicine, 1997
- PSA levels and the rate of positive surgical margins in radical prostatectomy specimens preceded by androgen blockade in clinical B2 (T2bNxMo) prostate cancerUrology, 1997
- A New Long Acting Formulation of the Luteinizing Hormone-Releasing Hormone Analogue, Goserelin: Results of Studies in Prostate CancerJournal of Urology, 1996
- Neoadjuvant Hormonal Therapy Before Radical Prostatectomy Decreases the Number of Positive Surgical Margins in Stage T2 Prostate Cancer: Interim Results of a Prospective Randomized TrialJournal of Urology, 1995
- Intermittent androgen suppression in the treatment of prostate cancer: A preliminary reportUrology, 1995
- Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the radiation therapy oncology groupUrology, 1995
- Zoladex versus orchiectomy in treatmentof advanced prostate cancer: a randomized trialUrology, 1991
- Effect of Hormonal Therapy on Plasma Testosterone Levels in Prostatic CarcinomaBMJ, 1971